Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To assess efficacy, safety, and tolerability of the preservative-free (PF) fixed-dose combination (FC) of tafluprost 0.0015%/timolol 0.5% (PF tafluprost/timolol FC) in treatments-naive patients with primary open-angle glaucoma (POAG). Methods: This was a retrospective, real-world clinical practice setting study that included 107 eyes of 107 subjects with POAG who had never been treated for glaucoma. All subjects were received PF tafluprost/timolol FC once daily. Intraocular pressure (IOP) levels were documented for each eye at the untreated baseline and up to 6 months after the initiation of medical treatment. All adverse events, including ocular and systemic adverse reactions, were recorded. Additionally, the reasons for medication discontinuations were thoroughly documented. Results: A total of 32 POAG patients with high-baseline IOP (>21 mmHg) and 75 with normal-baseline IOP were included in the study. The subjects’ baseline mean age was 62.4 ± 8.7 years (range, 26.0–85.0 years); among them, 42 were female (39.3%). Mean IOP at baseline for all patients was 18.6 ± 4.3 mmHg. The mean IOP at 6 months was 12.6 ± 4.7 mmHg, representing a significant decrease compared to the baseline (–32%, p < 0.001). In POAG patients with high-baseline IOP, mean IOP was significantly lowered from 28.0 ± 5.7 mmHg at baseline to 18.0 ± 5.5 mmHg (–35%, p < 0.001); in patients with normal-baseline IOP, from 14.6 ± 3.4 mmHg at baseline to 10.3 ± 4.1 mmHg (–29%, p < 0.001). PF tafluprost/timolol FC was well-tolerated and safe. After 6 months, 97.2% of all patients remained on therapy. Conclusions: In this real-world observational study, once-daily treatment with PF tafluprost/timolol FC demonstrated clinically relevant and statistically significant efficacy, as well as safety and good tolerability, in treatment-naive patients diagnosed with POAG.
Abstract
Purpose: To assess efficacy, safety, and tolerability of the preservative-free (PF) fixed-dose combination (FC) of tafluprost 0.0015%/timolol 0.5% (PF tafluprost/timolol FC) in treatments-naive patients with primary open-angle glaucoma (POAG). Methods: This was a retrospective, real-world clinical practice setting study that included 107 eyes of 107 subjects with POAG who had never been treated for glaucoma. All subjects were received PF tafluprost/timolol FC once daily. Intraocular pressure (IOP) levels were documented for each eye at the untreated baseline and up to 6 months after the initiation of medical treatment. All adverse events, including ocular and systemic adverse reactions, were recorded. Additionally, the reasons for medication discontinuations were thoroughly documented. Results: A total of 32 POAG patients with high-baseline IOP (>21 mmHg) and 75 with normal-baseline IOP were included in the study. The subjects’ baseline mean age was 62.4 ± 8.7 years (range, 26.0–85.0 years); among them, 42 were female (39.3%). Mean IOP at baseline for all patients was 18.6 ± 4.3 mmHg. The mean IOP at 6 months was 12.6 ± 4.7 mmHg, representing a significant decrease compared to the baseline (–32%, p < 0.001). In POAG patients with high-baseline IOP, mean IOP was significantly lowered from 28.0 ± 5.7 mmHg at baseline to 18.0 ± 5.5 mmHg (–35%, p < 0.001); in patients with normal-baseline IOP, from 14.6 ± 3.4 mmHg at baseline to 10.3 ± 4.1 mmHg (–29%, p < 0.001). PF tafluprost/timolol FC was well-tolerated and safe. After 6 months, 97.2% of all patients remained on therapy. Conclusions: In this real-world observational study, once-daily treatment with PF tafluprost/timolol FC demonstrated clinically relevant and statistically significant efficacy, as well as safety and good tolerability, in treatment-naive patients diagnosed with POAG.
참고문헌 (25)
- Oddone F, "Reviewing the evidence surrounding preservative-free tafluprost", timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management:a focus on efficacy, safety, and tolerability, 2022, pp.21, 1259~1268
- "European Glaucoma Society terminology and guidelines for glaucoma, 5th edition", Br J Ophthalmol, 105(Suppl 1), pp.1~169 (2021)
- White A, "Asia Pacific glaucoma guidelines" (2016), Kugler Publications
- "ICO guidelines for glaucoma care" (2016)[URL]
- Kass MA, "The Ocular Hypertension Treatment Study : a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma", Arch Ophthalmol, 120, pp.701~713 (2002)
- Stewart WC, "Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union", Eur J Ophthalmol, 19, pp.588~593 (2009)
- Baudouin C, "Detrimental effect of preservatives in eyedrops : implications for the treatment of glaucoma", Acta Ophthalmol, 86, pp.716~726 (2008)
- Kastelan S, "How ocular surface disease impacts the glaucoma treatment outcome", Biomed Res Int, 2013, pp.696328~ (2013)
- Aguayo Bonniard A, "Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride(BAK)", Expert Opin Drug Metab Toxicol, 12, pp.1279~1289 (2016)
- Leung EW, "Prevalence of ocular surface disease in glaucoma patients", J Glaucoma, 17, pp.350~355 (2008)
- Garcia-Feijoo J, "A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma", Clin Ophthalmol, 6, pp.441~446 (2012)
- Quaranta L, "Quality of life in glaucoma : a review of the literature", Adv Ther, 33, pp.959~981 (2016)
- Pisella PJ, "Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication", Br J Ophthalmol, 86, pp.418~423 (2002)
- Boimer C, "Preservative exposure and surgical outcomes in glaucoma patients : the PESO study", J Glaucoma, 22, pp.730~735 (2013)
- Perez-Garcia P, "Prescription trends for preservative free glaucoma medication in a public health system", Eur J Ophthalmol, 34, pp.193~203 (2024)
- Phillips AJ, "CCLRU grading scales(appendix D)", Contact Lens, 819, pp.863~867 (1997)
- Arbabi A, "Systemic side effects of glaucoma medications", Clin Exp Optom, 105, pp.157~165 (2022)
- Pfeiffer N, "A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components", Adv Ther, 31, pp.1228~1246 (2014)
- Hollo G, "Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%", timolol 0.5% versus concomitant use of the ingredients, 2014, pp.30, 468~475
- Pillunat LE, "Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension:results of an open-label observational study", Clin Ophthalmol, 11, pp.1051~1064 (2017)
- Song BJ, "New directions in the treatment of normal tension glaucoma", Indian J Ophthalmol, 62, pp.529~537 (2014)
- Tapply I, "Improving adherence to topical medication in patients with glaucoma", Patient Prefer Adherence, 15, pp.1477~1489 (2021)
- Radcliffe NM, "The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies", Clin Ophthalmol, 8, pp.2541~2549 (2014)
- Choe S, "Placebo effect and its determinants in ocular hypotensive therapy : meta-analysis and multiple meta-regression analysis", Ophthalmology, 130, pp.1149~1161 (2023)
- Alm A, "Side effects associated with prostaglandin analog therapy", Surv Ophthalmol, 53(Suppl1), pp.S93~S105 (2008)